REBIF 132 MCG / 1.5 ML
INTERFERON BETA-1A : 132 MCG / 1.5 ML · DIN 02318261 · EMD SERONO, A DIVISION OF EMD INC., CANADA
Health Canada status: MARKETED
What is REBIF?
REBIF 132 MCG / 1.5 ML contains INTERFERON BETA-1A : 132 MCG / 1.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02318261, held by EMD SERONO, A DIVISION OF EMD INC., CANADA, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 14-May-2009. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is REBIF used for?
REBIF (Interferon beta-1a Injection) is indicated for: The treatment of relapsing forms of multiple sclerosis (MS), to reduce the number and severity of clinical exacerbations, slow the progression of physical disability, reduce the requirement for steroids, reduce the number of hospitalizations for treatment of multiple sclerosis, and reduce T1 - Gd enhanced and T2 (burden of disease) lesions as seen on MRI. The treatment of patients who have experienced a single demyelinating event, accompanied by an active inflammatory process and an abnormal MRI scan with lesions typical of MS, who are determined to be at high risk of developing clinically definite multiple sclerosis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02318261 |
|---|---|
| Brand name | REBIF |
| Generic / active ingredient | INTERFERON BETA-1A : 132 MCG / 1.5 ML |
| Manufacturer | EMD SERONO, A DIVISION OF EMD INC., CANADA |
| Strength | 132 MCG / 1.5 ML |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Schedule D |
| ATC code | L03AB07 INTERFERON BETA-1A |
| AHFS class | 92:20.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 14-May-2009 |
| Original market date | 2009-05-14 00:00:00 |
How is it stored and handled?
null
How is it supplied?
22 mcg/0.5 mL and 44 mcg/0.5mL in pre-filled syringes supplied as 3-packs; 66 mcg/1.5 mL and 132 mcg/1.5 mL in pre-filled cartridges supplied as 4 pre-filled cartridges per box
What can be used instead?
Other Canadian products sharing ATC code L03AB07 INTERFERON BETA-1A. 5 of 11 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AVONEX | 30 MCG / 0.5 ML | SOLUTION | BIOGEN CANADA INC | MARKETED | DIN 02269201 |
| REBIF | 22 MCG / 0.5 ML | SOLUTION | EMD SERONO, A DIVISION OF EMD INC., CANADA | MARKETED | DIN 02237319 |
| REBIF | 44 MCG / 0.5 ML | SOLUTION | EMD SERONO, A DIVISION OF EMD INC., CANADA | MARKETED | DIN 02237320 |
| REBIF | 66 MCG / 1.5 ML | SOLUTION | EMD SERONO, A DIVISION OF EMD INC., CANADA | MARKETED | DIN 02318253 |
| AVONEX | 1.1 ML | POWDER FOR SOLUTION | BIOGEN CANADA INC | CANCELLED POST MARKET | DIN 02237770 |
| AVONEX | 60 MCG | POWDER FOR SOLUTION | BIOGEN CANADA INC | APPROVED | DIN 02267594 |
| REBIF | 132 MCG / 1.5 ML | SOLUTION | EMD SERONO, A DIVISION OF EMD INC., CANADA | CANCELLED PRE MARKET | DIN 02318288 |
| REBIF | 2 ML | LIQUID ; KIT ; POWDER | EMD SERONO, A DIVISION OF EMD INC., CANADA | CANCELLED POST MARKET | DIN 02237317 |
| REBIF | 8.8 MCG / 0.2 ML | POWDER FOR SOLUTION ; KIT ; LIQUID | EMD SERONO, A DIVISION OF EMD INC., CANADA | CANCELLED POST MARKET | DIN 02281708 |
| REBIF | 8.8 MCG / 0.2 ML | SOLUTION | EMD SERONO, A DIVISION OF EMD INC., CANADA | CANCELLED POST MARKET | DIN 02277492 |
Who else supplies INTERFERON BETA-1A worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. INTERFERON BETA-1A appears in 84 registered pack listings across 12 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.